Total Payments
$26,499
2024 Payments
$5,980
Companies
7
Transactions
26
Payment Breakdown by Category
Research$24,311 (91.7%)
Travel$1,165 (4.4%)
Food & Beverage$1,023 (3.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $24,311 | 11 | 91.7% |
| Travel and Lodging | $1,165 | 3 | 4.4% |
| Food and Beverage | $1,023 | 12 | 3.9% |
Payments by Type
Research
$24,311
11 transactions
General
$2,188
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $19,826 | 12 | $0 (2023) |
| Eli Lilly Export S.A. Puerto Rico Branch | $5,945 | 4 | $0 (2024) |
| Novo Nordisk Inc | $238.01 | 3 | $0 (2024) |
| Lilly USA, LLC | $190.06 | 4 | $0 (2024) |
| ABBVIE INC. | $125.00 | 1 | $0 (2023) |
| Amgen Inc. | $99.60 | 1 | $0 (2022) |
| GENZYME CORPORATION | $74.84 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,980 | 7 | Eli Lilly Export S.A. Puerto Rico Branch ($5,742) |
| 2023 | $4,638 | 10 | Eli Lilly and Company ($4,262) |
| 2022 | $15,881 | 9 | Eli Lilly and Company ($15,564) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/15/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $86.36 | General |
| 09/27/2024 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | Cash or cash equivalent | $716.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | ||||||
| 09/23/2024 | Eli Lilly Export S.A. Puerto Rico Branch | — | — | Cash or cash equivalent | $4,934.00 | Research |
| Study: A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | ||||||
| 08/09/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $74.84 | General |
| Category: Immunology | ||||||
| 06/24/2024 | Eli Lilly Export S.A. Puerto Rico Branch | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $92.13 | General |
| Category: Obesity | ||||||
| 06/22/2024 | Lilly USA, LLC | JARDIANCE (Drug), MOUNJARO, ZEPBOUND | Food and Beverage | In-kind items and services | $37.92 | General |
| Category: Diabetes | ||||||
| 06/21/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $38.47 | General |
| 08/21/2023 | Eli Lilly and Company | — | — | In-kind items and services | $200.45 | Research |
| Study: A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | ||||||
| 07/24/2023 | Eli Lilly Export S.A. Puerto Rico Branch | — | Food and Beverage | Cash or cash equivalent | $203.32 | General |
| 05/26/2023 | Lilly USA, LLC | JARDIANCE (Drug), LYUMJEV, MOUNJARO | Food and Beverage | In-kind items and services | $47.90 | General |
| Category: Diabetes | ||||||
| 05/25/2023 | Eli Lilly and Company | — | — | In-kind items and services | $852.54 | Research |
| Study: A PHASE 3 12 MONTH OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | ||||||
| 04/19/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 03/06/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $595.40 | General |
| 03/06/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $287.97 | General |
| 03/06/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $281.97 | General |
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $757.69 | Research |
| Study: PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | ||||||
| 01/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $1,286.11 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | ||||||
| 12/29/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $8,934.00 | Research |
| Study: PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | ||||||
| 12/29/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $4,684.00 | Research |
| Study: A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | ||||||
| 12/22/2022 | Eli Lilly and Company | — | — | In-kind items and services | $456.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | ||||||
| 12/08/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $68.45 | General |
| Category: Diabetes | ||||||
| 11/03/2022 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $113.18 | General |
| Category: Diabetes | ||||||
| 10/19/2022 | Eli Lilly and Company | — | — | In-kind items and services | $239.00 | Research |
| Study: A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | ||||||
| 10/05/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,251.00 | Research |
| Study: PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | ||||||
| 08/22/2022 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $99.60 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $10,185 | 2 |
| A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | Eli Lilly Export S.A. Puerto Rico Branch | $4,934 | 1 |
| A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | Eli Lilly and Company | $4,923 | 2 |
| A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $1,286 | 1 |
| A PHASE 3 12 MONTH OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | Eli Lilly and Company | $852.54 | 1 |
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $757.69 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly Export S.A. Puerto Rico Branch | $716.00 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $456.00 | 1 |
| A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | Eli Lilly and Company | $200.45 | 1 |
About Dr. Elham Ghorbani, MD
Dr. Elham Ghorbani, MD is a General Practice healthcare provider based in Dorado, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2022. The National Provider Identifier (NPI) number assigned to this provider is 1407517246.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Elham Ghorbani, MD has received a total of $26,499 in payments from pharmaceutical and medical device companies, with $5,980 received in 2024. These payments were reported across 26 transactions from 7 companies. The most common payment nature is "" ($24,311).
Ad
Practice Information
- Specialty General Practice
- Location Dorado, PR
- Active Since 01/04/2022
- Last Updated 03/22/2022
- Taxonomy Code 208D00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1407517246
Products in Payments
- RINVOQ (Biological) $125.00
- JARDIANCE (Drug) $121.61
- Rybelsus (Drug) $113.18
- Aimovig (Biological) $99.60
- ZEPBOUND (Drug) $92.13
- DUPIXENT (Biological) $74.84
- MOUNJARO (Drug) $68.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
General Practice Doctors in Dorado
Dr. Luis Pagan, Md, MD
General Practice — Payments: $144,099
General Practice $144,099
Luis Pena Figueroa, M.d, M.D
General Practice — Payments: $2,482
General Practice $2,482
Carlos Robles
General Practice — Payments: $2,078
General Practice $2,078
Dr. Richard Connelly, M.d, M.D
General Practice — Payments: $1,203
General Practice $1,203
Mr. Blanca Plaza, Md, MD
General Practice — Payments: $863.32
General Practice $863.32
Melitsa Aguilar, M.d, M.D
General Practice — Payments: $737.23
General Practice $737.23